When you hear about a big pharmaceutical company buying a smaller biotech firm, it might seem like just another business deal, but it significantly impacts the medicines you might use someday. This lesson will show you why these acquisitions are crucial for developing new drugs and what Merck's recent move means for future treatments.
Merck's acquisition of Terns Pharmaceuticals is trending because it's a prime example of a common strategy in the drug industry: big pharma buying promising biotech.
Merck recently announced its intent to acquire Terns Pharmaceuticals, a clinical-stage biotech company.